A panelist discusses how EGFR-mutated NSCLC treatment has evolved to include multiple generations of EGFR tyrosine kinase inhibitors as first-line therapy, with newer agents showing improved efficacy compared with earlier options.
Take this survey powered by surveymonkey.com. Create your own surveys for free.
“Our data suggest that the combination of sorafenib tosylate, valproic acid, and sildenafil requires additional clinical development in the recurrent glioma population,” the researchers wrote.
According to Jason Luke, MD, FACP, there is still room to improve response rates in CSCC treatment, but there is excitement surrounding future of treatment…
Imlunestrant with or without abemaciclib improved PFS in select patients with ER-positive, HER2-negative advanced breast cancer after endocrine therapy.
Santosh Saraf, MD, University of Illinois Hospital, Chicago, IL, comments on the concurrent administration of GBT1118 & losartan in a mouse model of kidney disease…
After her dad died of liposarcoma, Valeria Medrano wanted to do something to give back. She began donating blood to MD Anderson Blood Bank through…
Roger Li, MD, H. Lee Moffitt Cancer Center, Tampa, FL, provides a brief overview on the joint mechanism of action for oncolytic viruses and immune…
This Review describes why comprehensive molecular biomarker testing is now required for the accurate diagnosis and grading and prognostication of central nervous system tumors.
Neoadjuvant patritumab deruxtecan with or without letrozole produced pathologic complete responses in high-risk, HR-positive/HER2-negative breast cancer.
